Kathleen Laporte

Kathy LaPorte has more than 30 years of experience building and operating private and public biotech companies. She currently serves as a director of Elysium Therapeutics, Precipio Diagnostics and D2G Oncology. Kathy was chief executive officer of Nodality Inc. as well as a founding partner of New Leaf Ventures, which was a spinout from the Sprout Group. Prior to that, Kathy served as a general partner of The Sprout Group for over 12 years. She is passionate about helping founders, CEOs and organizations grow successfully and playing a meaningful role on outstanding boards. Kathy’s board experience is extensive and includes both private and public companies, as well as public-sector boards such as the California Institute of Regenerative Medicine (CIRM). She has served on more than a dozen public company boards, including companies such as Affymax, ISTA Pharmaceuticals, and Onyx Pharmaceuticals. Kathy has served on 12 audit committees, and chaired several. She is a Qualified Financial Expert. Kathy has a B.S. degree in Biology from Yale University and an M.B.A. from the Stanford University Graduate School of Business.